FDA calendar · May 2021 · built from SEC filings

PDUFA dates May 2021: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in May 2021. The FDA calendar also recorded 13 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in May 2021

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

May 2021: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
May 5, 2021KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
May 14, 2021Bosulif (bosutinib monohydrate)PFELabel expansion—ApprovedopenFDA Drugs@FDA
May 20, 2021Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 21, 2021Rybrevant (amivantamab-vmjw)JNJFDA approval—ApprovedopenFDA Drugs@FDA
May 25, 2021Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 27, 2021Zeposia (ozanimod hydrochloride)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
May 27, 2021Nurtec Odt (rimegepant sulfate)PFELabel expansion—ApprovedopenFDA Drugs@FDA
May 28, 2021Lybalvi (olanzapine; samidorphan l-malate)ALKSFDA approval—ApprovedopenFDA Drugs@FDA
May 28, 2021LUMYKRAS™ (sotorasib)AMGNFDA approval—ApprovedopenFDA Drugs@FDA
May 28, 2021Cosentyx (secukinumab)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
May 31, 2021Noxafil (posaconazole)MRKFDA approval—ApprovedopenFDA Drugs@FDA
May 31, 2021Noxafil (posaconazole)MRKLabel expansion—ApprovedopenFDA Drugs@FDA

May 2021: dated readouts

DateDrugCompanyEventIndicationStatusSource
May 2021Month disclosedAPHEXDA® (motixafortide)BLRXTopline readout—Met primary endpointSEC 8-K Exhibit 99.1

Questions

What PDUFA dates are in May 2021?

0 PDUFA dates fell in May 2021. The FDA calendar also recorded 13 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.